PMID- 30876919
OWN - NLM
STAT- MEDLINE
DCOM- 20200214
LR  - 20200214
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 165
DP  - 2019 Jul
TI  - Useful message in choosing optimal biological agents for patients with autoimmune 
      arthritis.
PG  - 99-111
LID - S0006-2952(19)30093-0 [pii]
LID - 10.1016/j.bcp.2019.03.007 [doi]
AB  - The introduction of biological disease-modifying antirheumatic drug (bDMARD) 
      treatments for various types of autoimmune arthritis, such as rheumatoid 
      arthritis, psoriatic arthropathy and ankylosing spondylitis, represents a new era 
      of treatment for patients with a refractory response to conventional synthetic 
      DMARDs (csDMARDs). Many new bDMARDs with different modalities or that target 
      different pro-inflammatory molecules, likely cytokines, are rapidly emerging. 
      Hence, physicians in the field may be confused about choosing appropriate bDMARDs 
      for their patients. Considering the high cost of bDMARDs and the rapid 
      destructive process of autoimmune arthritis in patients, the choice of optimal 
      bDMARDs for patients who fail to respond or show an inadequate therapeutic 
      response to csDMARDs designed to control the disease is very critical. Here, we 
      summarize the strengths and weaknesses of bDMARDs and specifically focus on their 
      uses in patients with comorbid conditions or with specific medical conditions, 
      such as pregnancy. This commentary provides a solid up-to-date review on 
      commercially available bDMARDs and very useful information for physicians to 
      facilitate the choice of more appropriate bDMARDs to treat patients with 
      autoimmune arthritis and for basic researchers to understand the current 
      strategies of bDMARD usage and hopefully to develop more powerful bDMARDs with 
      fewer safety concerns.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Lai, Jenn-Haung
AU  - Lai JH
AD  - Division of Allergy, Immunology, and Rheumatology, Department of Internal 
      Medicine, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan, Taiwan, 
      ROC; Graduate Institute of Medical Science, National Defense Medical Center, 
      Taipei, Taiwan, ROC. Electronic address: laiandho@gmail.com.
FAU - Ling, Xiao Chun
AU  - Ling XC
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Chang Gung University, 
      Tao-Yuan, Taiwan, ROC.
FAU - Ho, Ling-Jun
AU  - Ho LJ
AD  - Institute of Cellular and System Medicine, National Health Research Institute, 
      Zhunan, Taiwan, ROC. Electronic address: lingjunho@nhri.org.tw.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190313
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Factors)
SB  - IM
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Biological Factors/adverse effects/*therapeutic use
MH  - Humans
MH  - Patient Safety
MH  - Spondylitis, Ankylosing/*drug therapy
OTO - NOTNLM
OT  - Autoimmune arthritis
OT  - Biological disease-modifying antirheumatic drug
OT  - Therapeutics
EDAT- 2019/03/17 06:00
MHDA- 2020/02/15 06:00
CRDT- 2019/03/17 06:00
PHST- 2019/01/12 00:00 [received]
PHST- 2019/03/07 00:00 [accepted]
PHST- 2019/03/17 06:00 [pubmed]
PHST- 2020/02/15 06:00 [medline]
PHST- 2019/03/17 06:00 [entrez]
AID - S0006-2952(19)30093-0 [pii]
AID - 10.1016/j.bcp.2019.03.007 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2019 Jul;165:99-111. doi: 10.1016/j.bcp.2019.03.007. Epub 2019 
      Mar 13.